PET-CT imaging facility

The primary use of the Positron Emission Tomography (PET) / Computed Tomography (CT) system is for the development and validation of novel radiolabeled positron emitting ligands which can be used for tumor detection, diagnosis of autoimmune disease or establishing metabolic pathways.

Siemens Inveon PET-CT

New Siemens Inveon PET-CT (formerly Concord Focus) system uses high light output LSO (Lutetium Oxyorthosilicate) crystals, and has a timing resolution of less than 1.5 nsec, greater than 10% peak absolute sensitivity, a stationary FOV of 12.7 cm (which can increase to 30 cm FOV with continuous bed motion), an energy resolution of less than 18%, over 25,000 individual detector elements, and a spatial resolution of less than 1.4 mm. The CT uses CCD technology that allows the highest available signal-to-noise ratio, and fiber optics that permit the highest efficiency light collection. It has 4,064 x 4,064 detectors, a FOV greater than 10 x 10 cm, a spatial resolution of 15 micron isotropic voxels, and can scan an entire mouse in less than 1 min.

The primary use of the Siemens Inveon PET-CT is for the development and validation of novel radiolabeled positron emitting ligands which can be used for tumor detection, diagnosis of autoimmune disease or establishing metabolic pathways.

Inveon Pet

GammaMedica X-PET

The imaging system used is Gamma Medica FLEX XPET / XO small animal imaging system. The XPET system has the highest sensitivity and largest axial field of view among small animal PET scanners. The 3D PET system is comprised of 11520 (2.3 mm x 2.38 mm x 10 mm) Bismuth Germanate (BGO) crystals in 48 separate rings. The large axial field of view (11.6 cm) can image an entire mouse with a resolution less than 2 mm.

Pet

Publications

  1. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik D, Aikawa E, Libby P, Swirski F, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis Circulation. 2007; :ePub
  2. Rudin, M. and Weissleder, R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003;2:123-31